For Sponsors and CROs
The Cardiovascular Site That Hits Your Enrollment Numbers -- and the Diversity Your Reviewers Now Demand
Senior PI is Dr. William W. O'Neill, U.S. TAVR pioneer and National PI on Edwards PARTNER, Protect II, and Protect IV. Sixteen-plus pharma sponsors. ICH-GCP E6(R3) compliant. The only dedicated cardiovascular ASC in South Florida sits 12 miles from our front door. Hispanic, Haitian, and Caribbean enrollment baked in -- your FDA Diversity Action Plan, already covered.
Trusted by Alnylam / Pfizer / Pharmacosmos / JK07 Bio / VASA Therapeutics / Cardiovascular Systems / 10 more.
Why Amavita
Six reasons sponsors choose Amavita Research as their Miami site partner.
IAOCR GCSA Certified
Sponsor audit prep, condensed. GCSA is the only ISO-style site accreditation in clinical research. We hold it. Your monitor does not have to verify what an independent body has already certified.
ICH-GCP E6 (R3) Compliant
Already operating to E6(R3). When your protocol crosses a regulator's desk, our quality systems are not a question -- they are a footnote.
Blue-Chip Track Record
Trusted by 16+ sponsors including Alnylam, Pfizer, Pharmacosmos, JK07 Bio, and VASA Therapeutics. The same sponsors keep coming back for their second and third study with us -- that is the data point that matters.
Top-5 CV Site, Southeast US
Top-5 cardiovascular site in the Southeast US, by enrollment. The fewer competing sites in your study tier, the more your timeline depends on the ones that perform. We are one of them.
Diverse Miami Population
Hispanic, Haitian, and Caribbean recruitment baked in. With FDA Diversity Action Plans now mandatory for Phase 3 cardiovascular trials, our zip code is a regulatory moat -- not a marketing line.
Dedicated BD Contact
One contact: Nereisy Alonso, Sr CRC. Feasibility, budget, contracts, monitor access -- answered the same business day. No swivel-chair across four people on your CRO call.
A Senior PI with a track record of FDA-pivotal device trial leadership
Our Senior Principal Investigator Dr. William W. O'Neill, MD, FACC has served as National Principal Investigator on the Edwards PARTNER, Protect II, and Protect IV trials — a track record of FDA-pivotal device trial leadership matched by few investigators in the United States.
South Florida's only dedicated cardiovascular ambulatory surgery center
Sponsors partnering with Amavita Research gain access to South Florida's only dedicated cardiovascular ASC — enabling complex device and structural-heart studies, same-day procedures, and a controlled outpatient setting that streamlines protocol execution and reduces hospital-based variability.
ASC Capabilities
Procedures supported on-site
Complex device, structural-heart, and interventional studies executed in a controlled outpatient setting — reducing hospital-based variability.
Cardiology
- Cardiac Catheterization
- Cardiac Mapping & Ablation
- Coronary Intervention
- Implantable Cardiac Monitors
- Pacemakers / ICDs / Bi-Ventricular Devices
- Peripheral Artery & Vein Angiography & Intervention
Interventional Radiology
- Dialysis Access Management
- Genicular / Hemorrhoidal / Prostate Artery Embolization
- Kyphoplasty
- Spinal Cord Stimulator Implantation
- Uterine Fibroid Embolization
Technology
Capabilities that move your study forward
From feasibility through close-out, our team operates as a true extension of yours — bringing deep cardiometabolic experience and the infrastructure to execute complex protocols.
Therapeutic Expertise
Deep experience across cardiology, heart failure (HFrEF/HFpEF), hypertension, ACS, vascular and metabolic studies — Phase 1 through Phase 3.
Modern Recruitment Technology
EHR-integrated patient identification, predictive screening, and a digital pre-screening funnel that accelerates enrollment.
Trained, Bilingual Staff
Board-certified PI, study coordinators, and regulatory specialists fluent in English and Spanish.
Miami-Area Patient Diversity
Access to one of the most ethnically and clinically diverse patient populations in the United States.
Trusted by leading sponsors
- Alnylam Pharmaceuticals
- Pfizer
- JK07 Bio
- VASA Therapeutics
- Pharmacosmos
- Cardiovascular Systems
- Boehringer Ingelheim
- Novartis
- AstraZeneca
- Bristol Myers Squibb
- Merck
- Bayer
- Eli Lilly
- Amgen
- Sanofi
- Gilead
16+ pharmaceutical and biotech partners — selection shown
Track Record - Numbers, Not Adjectives
Performance you can underwrite
Below is what makes sponsors expand from one study to three.
- 7 active Phase 1-3 cardiovascular trials, scaling to 18-25 by year-end
- 16+ pharma sponsors signed (and re-signed)
- Enrollment targets met or exceeded -- every cycle
- Audit-ready SOPs from day one (GCSA standard)
- Sub-2-week IRB submission
- Contract turnaround in days, not quarters
- SCRS Global Summit participant -- we sit at the table
Business Development
Nereisy Alonso, Sr CRC
Business Development Director
Schedule a Sponsor ConsultationFAQ
Frequently Asked Questions
Quick answers about our certifications, leadership, and sponsor partnerships.